Success Metrics

Clinical Success Rate
85.3%

Based on 29 completed trials

Completion Rate
85%(29/34)
Active Trials
2(4%)
Results Posted
31%(9 trials)
Terminated
5(11%)

Phase Distribution

Ph phase_1
7
15%
Ph not_applicable
9
20%
Ph phase_2
11
24%
Ph phase_3
8
17%
Ph phase_4
11
24%

Phase Distribution

7

Early Stage

11

Mid Stage

19

Late Stage

Phase Distribution46 total trials
Phase 1Safety & dosage
7(15.2%)
Phase 2Efficacy & side effects
11(23.9%)
Phase 3Large-scale testing
8(17.4%)
Phase 4Post-market surveillance
11(23.9%)
N/ANon-phased studies
9(19.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.9%

29 of 35 finished

Non-Completion Rate

17.1%

6 ended early

Currently Active

2

trials recruiting

Total Trials

46

all time

Status Distribution
Active(2)
Completed(29)
Terminated(6)
Other(9)

Detailed Status

Completed29
unknown9
Terminated5
Withdrawn1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
46
Active
2
Success Rate
85.3%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (15.2%)
Phase 211 (23.9%)
Phase 38 (17.4%)
Phase 411 (23.9%)
N/A9 (19.6%)

Trials by Status

withdrawn12%
active_not_recruiting12%
recruiting12%
unknown920%
completed2963%
terminated511%

Recent Activity

Clinical Trials (46)

Showing 20 of 46 trialsScroll for more
NCT07757867Not Applicable

Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata

Completed
NCT06666855Phase 3

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

Active Not Recruiting
NCT02390284Phase 3

Stop Retinal Ganglion Cell Dysfunction Study

Terminated
NCT06239324Phase 1

Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser

Recruiting
NCT00579969Phase 2

Comparison of Latanoprost Vs. Timolol

Terminated
NCT00572936Phase 2

Circadian Rhythms of Aqueous Humor Dynamics in Humans

Completed
NCT04811326Phase 4

Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation

Unknown
NCT00934089Phase 2

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

Completed
NCT04737928Not Applicable

Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

Completed
NCT00716859Phase 3

A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.

Completed
NCT00647101Phase 4

A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma

Completed
NCT00638742Phase 1

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

Completed
NCT00846989Phase 1

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

Completed
NCT04178863Phase 4

CATS Tonometer IOP Reduction Latanoprost Verses Timolol

Unknown
NCT03419975Phase 3

A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients

Completed
NCT02656979Not Applicable

Blood Flow of Ophthalmic Artery and Glaucoma

Unknown
NCT03966560Phase 4

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma

Completed
NCT03762369Phase 3

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Unknown
NCT03611348Phase 2

Microneedling and Latanoprost in Acrofacial Vitiligo

Unknown
NCT03480906Not Applicable

Eyenovia MiDD Usability Study

Completed

Drug Details

Intervention Type
DRUG
Total Trials
46